

PATENT  
Docket No. 265.00390101

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al.	)	Group Art Unit:	1617	RECEIVED CENTRAL FAX CENTER
	)			NOV 11 2004
Serial No.: 10/691,330	)	Examiner:	Unknown	
Confirmation No.: 1384	)			
	)			
Filed: October 22, 2003	)			
	)			
	)			

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

FACSIMILE TRANSMISSION TO THE PTO

Commissioner for Patents  
Attn: Mail Stop Amendment  
P.O. Box 1450  
Alexandria, VA 22313-1450

FAX NUMBER: (703) 872-9306  
Total Pages (including cover page): 18  
Time: 10:42 am (Central Time)  
(Transmission must be complete by midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: Supplemental Information Disclosure Statement (2 pgs.); 1449 Form (1 pg.); copy of 1 reference cited on the 1449 form (14 pgs.)

X Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Muetting, Raasch & Gebhardt, P.A.  
Customer Number: 26813

November 11, 2004  
Date

By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

CERTIFICATE UNDER 37 C.F.R. 81.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Attn: Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11th day of November, 2004, at 10:42 am (Central Time).

Nov. 11, 2004  
Date

Signature: Sara E. Olson  
Name: Sara E. Olson

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

PATENT  
Docket No. 265.00390101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al. ) Group Art Unit: 1617  
                               )  
Serial No.: 10/691,330      ) Examiner: Unknown  
Confirmation No.: 1384       )  
                               )  
Filed: October 22, 2003     )  
                               )  
                               )

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND  
ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR  
DAMAGE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
CENTRAL FAX CENTER

NOV 11 2004

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

**Supplemental Information Disclosure Statement**

Page 2 of 2

Applicant: Boldogh et al.

Serial No.: 10/691,330

Filed: October 22, 2003

**Title: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE**

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

Respectfully submitted for

**Boldogh et al.**

By

Mueting, Raasch &amp; Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415


Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

**CERTIFICATE UNDER 37 C.F.R. 1.8:**

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11<sup>th</sup> day of November, 2004, at 10:42 am (Central Time).

  
Name: Sara E. OlsonNovember 11, 2004

Date

  
By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

OMB No. 0651-0011  
Page 1 of 1

<b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No.: 265.00390101	Serial No.: 10/691,330
	Applicant(s): Boldogh et al.	Confirmation No.: 1384
	Application Filing Date: October 22, 2003	Group: 1617
	Information Disclosure Statement mailed: November 11, 2004	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Copy Enclosed	Document Description
	X	Jurgens et al., "Modification of Human Low-Density Lipoprotein by the Lipid Peroxidation Product 4-Hydroxynonenal," <i>Biochem Biophys.</i> , January 1986;875:103-114.

RECEIVED  
CENTRAL FAX CENTER

NOV 11 2004

<b>EXAMINER</b>	<b>Date Considered</b>
-----------------	------------------------

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.